Efficacy of DPP-4 inhibitors for oxidative stress and inflammation in type 2 diabetic patients

Efficacy of DPP-4 inhibitors for oxidative stress and inflammation in type 2 diabetic patients - Efficacy of DPP-4 inhibitors for oxidative stress and inflammation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019022

Enrollment

200

Registered

2015-09-15

Start date

2013-05-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetic patients

Interventions

Subjects who have not administered DPP-4 inhibitors were allocated randomly to either vildagliptin 100 mg/day or alogliptin 25 mg/day during 6 months. Subjects who have not administered DPP-4 inhibito

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Outpatients with type 2 diabetes who have not administered alogliptin or vildagliptin. 2)Subjects who give consent document about participation in the clinical study

Exclusion criteria

Exclusion criteria: (1) With diabetic ketoacidosis, diabetic coma and type 1 diabetes (2) With severe infection (3) Subjects who have administered insulin or glinide (4) With severe liver dysfuction (5) With severe kidney dysfunction (6) Considered as inadequate by the investigator

Design outcomes

Primary

Measure	Time frame
change of HbA1c at 12 and 24 weeks	—

Countries

Japan

Contacts

Public ContactKenichi Tanaka

University of Occupational and Environmental Health First Department of Internal Medicine, School of Medicine

kenichi.tanaka0801@gmail.com0936031611

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026